Peroral Administration of Antidiuretic Peptides to Conscious Dogs, Normal Humans and Patients with Diabetes insipidus

2015 ◽  
pp. 314-320 ◽  
Author(s):  
Hans Vilhardt ◽  
Mogens Hammer ◽  
Peter Bie
Keyword(s):  
Diabetes Insipidus ◽  
Conscious Dogs ◽  
Peroral Administration ◽  
Patients With Diabetes ◽  
Normal Humans

Sweat Tests in Patients with Diabetes Insipidus

1988 ◽  
Vol 27 (7) ◽  
pp. 330-332 ◽  
Author(s):  
Eileen Doherty-Fuller ◽  
Kenneth C. Copeland
Keyword(s):  
Diabetes Insipidus ◽  
Patients With Diabetes ◽  
Sweat Tests

Long-Term Therapy of Diabetes Insipidus with Oral Benzothiadiazine and Phthalimidine Diuretics

1971 ◽  
Vol 40 (6) ◽  
pp. 497-511 ◽  
Author(s):  
A. F. Lant ◽  
G. M. Wilson
Keyword(s):  
Diabetes Insipidus ◽  
Diuretic Therapy ◽  
Term Therapy ◽  
Body Sodium ◽  
Combined Administration ◽  
Patients With Diabetes ◽  
Term Basis ◽  
Sodium Metabolism ◽  
Long Term Therapy

1. The antidiuretic effects of oral therapy with benzothiadiazine and phthalimidine diuretics have been studied in seven patients with diabetes insipidus of pituitary origin. 2. The immediate and chronic phases of diuretic-induced antidiuresis differ in their characteristics. Immediate antidiuresis is closely related both to the saluretic action of the diuretics and to the level of fluid turnover prevailing before their administration. By contrast, the findings in four patients maintained on polythiazide or clorexolone for at least 4 years show that antidiuresis persists at a time when saluretic effects have ceased and there is no longer any detectable disturbance in body sodium metabolism. A change in mechanism of antidiuresis appears to occur with the passage of time. 3. There is a parallelism between the characteristics of the chronic antidiuretic and antihypertensive actions of diuretics. The mechanism of both effects remains obscure. 4. Despite uncertainty as to mechanism, diuretic therapy offers a reliable means of treating diabetes insipidus on a long-term basis. The only complication encountered was symptomless hypokalaemia which developed despite regular use of supplemental oral potassium. Combined administration of triamterene or amiloride with either polythiazide or clorexolone has been used with success as an alternative regime.

EFFECT OF A SYNTHETIC ANALOGUE OF VASOPRESSIN IN ANIMALS AND IN PATIENTS WITH DIABETES INSIPIDUS

The Lancet ◽  
1968 ◽  
Vol 291 (7549) ◽  
pp. 948-952 ◽  
Author(s):  
I. Vávra ◽  
A. Machová ◽  
V. Holecek ◽  
J.H. Cort ◽  
M. Zaoral ◽  
...  
Keyword(s):  
Diabetes Insipidus ◽  
Synthetic Analogue ◽  
Patients With Diabetes

scholarly journals Diabetes Insipidus as a Complication of Wegener's Granulomatosis and Its Treatment with Biologic Agents

2009 ◽  
Vol 2009 ◽  
pp. 1-4 ◽  
Author(s):  
Joanna Rosalind Cunnington ◽  
Ramesh Jois ◽  
Ivan Zammit ◽  
David Scott ◽  
John Isaacs
Keyword(s):  
Pituitary Gland ◽  
Diabetes Insipidus ◽  
Wegener’S Granulomatosis ◽  
Standard Treatment ◽  
Rare Complication ◽  
Wegener's Granulomatosis ◽  
Biologic Agents ◽  
Response To Treatment ◽  
Biologic Therapies ◽  
Patients With Diabetes

Wegener's granulomatosis of the pituitary gland resulting in diabetes insipidus is a rare complication of the disease. Standard treatment for Wegener's granulomatosis involves a combination of prednisolone and cylophosphamide, however biologic agents are now being used in refractory cases. We report three cases of patients with diabetes insipidus as a complication of Wegener's granulomatosis who were treated with biologic agents. All three cases showed clinical response to treatment with biologic agents including rituximab and alemtuzumab and two cases demonstrated improvement in pituitary gland abnormalities by MRI. Clinicians should be aware that diabetes insipidus can present as a complication of Wegener's granulomatosis and that biologic therapies may be effective in refractory cases.

DDAVP IN DIABETES INSIPIDUS

1987 ◽  
Author(s):  
V Vicente ◽  
J Corrales ◽  
J Miralles ◽  
I Alberca
Keyword(s):  
Factor Viii ◽  
Diabetes Insipidus ◽  
Von Willebrand Factor ◽  
Therapeutic Dose ◽  
Healthy Subjects ◽  
Tissue Plasminogen ◽  
Patients With Diabetes ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Cranial Diabetes Insipidus

In order to investigate whether the response of von Willebrand factor (vWF), Factor VIII (FVIII) and tissue plasminogen activator (t-PA) to DDAVP infusion is governed by the integrity of the hypothaLamo neurohypophyseal axis, we studied the behaviours >of these proteins (FVIII, one stage; vWF antigen by electroimmunoassay and t-PA was measured in the plasma auglobulin fraction with added C-1 inactivator on fibrin plates) after DDAVP infusion (0.3 ug/Kg) in five patients with cranial diabetes insipidus, comparing them with the responses obtained in six healthy subjects.In spite of receiving a daily therapeutic dose of 10-20 ug of DDAVP the patients with diabetes insipidus showed normal basal levels of FVIII, vWF and t-PA. The increase in these parameters following DDAVP infusion were not significantly different in the two groups. These findings suggest that the integrity of the hypothalamo-hypophyseal axis is not neccessary for a response by vWF, FVIII and t-PA to occur after DDAVP infusion.

Effect of Arginine on the Hypothalamic–Pituitary–Adrenal Axis in Individuals With and Without Vasopressin Deficiency

2020 ◽  
Vol 105 (7) ◽  
pp. e2327-e2336
Author(s):  
Katja Bologna ◽  
Nicole Cesana-Nigro ◽  
Julie Refardt ◽  
Cornelia Imber ◽  
Deborah R Vogt ◽  
...  
Keyword(s):  
Diabetes Insipidus ◽  
Hpa Axis ◽  
Pituitary Hormones ◽  
University Hospital ◽  
Healthy Controls ◽  
Arginine Infusion ◽  
Hypothalamic Pituitary Adrenal ◽  
Primary Polydipsia ◽  
Patients With Diabetes ◽  
Different Response

Abstract Context Arginine stimulates pituitary hormones, like growth hormone and vasopressin, but its effect on the hypothalamic–pituitary–adrenal (HPA) axis is unknown. Arginine may also stimulate the HPA axis, possibly through a mechanism involving vasopressin. Objective To investigate the effect of arginine on adrenocorticotropic hormone (ACTH) and cortisol in subjects with and without vasopressin deficiency. Design Prospective study, University Hospital Basel. Participants 38 patients with central diabetes insipidus, 58 patients with primary polydipsia, and 50 healthy controls. Intervention Arginine infusion with measurement of ACTH, cortisol and copeptin at baseline and 30, 45, 60, 90, and 120 minutes. Results We found different response patterns to arginine: in patients with diabetes insipidus (and low stimulated copeptin levels) median (interquartile range [IQR]) ACTH and cortisol increased from 22.9 (16.8, 38.7) to 36.6 (26.2, 52.1) ng/L and from 385 (266, 463) to 467 (349, 533) nmol/L, respectively. In contrast, median (IQR) ACTH and cortisol levels decreased in patients with primary polydipsia (despite high stimulated copeptin levels): ACTH from 17.3 (12.3, 23) to 14.8 (10.9, 19.8) ng/L and cortisol from 343 (262, 429) to 272 (220.8, 360.3) nmol/L; likewise, in healthy controls: ACTH from 26.5 (17.6, 35.7) to 14.8 (12.1, 22.7) ng/L and cortisol from 471 (393.3, 581.8) to 301.5 (206.5, 377.8) nmol/L. Conclusion Diabetes insipidus is associated with increased responsiveness of ACTH/cortisol to arginine. In contrast, arginine does not stimulate the HPA axis in healthy controls or in primary polydipsia.

Sign in / Sign up

Export Citation Format

Share Document